Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
1.200
+0.130 (12.15%)
At close: Dec 5, 2025, 4:00 PM EST
1.150
-0.050 (-4.16%)
After-hours: Dec 5, 2025, 7:16 PM EST
Scinai Immunotherapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '25 Dec 5, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 4 | 3 | 3 | 10 | 43 | 32 | |
| Market Cap Growth | 59.38% | 10.12% | -74.89% | -76.24% | 34.05% | -65.34% | |
| Enterprise Value | 5 | 3 | 16 | 19 | 55 | 59 | |
| Last Close Price | 1.20 | 3.35 | 5.95 | 29.60 | 235.00 | 281.00 | |
| PS Ratio | 1.38 | 4.34 | - | - | - | - | |
| PB Ratio | 0.81 | 0.29 | -0.57 | -5.86 | 44.22 | -7.13 | |
| P/TBV Ratio | 1.71 | 0.66 | - | - | 44.22 | - | |
| EV/Sales Ratio | 4.53 | 4.63 | - | - | - | - | |
| EV/EBITDA Ratio | - | - | - | - | - | 21.29 | |
| EV/EBIT Ratio | - | - | - | - | - | 25.66 | |
| Debt / Equity Ratio | 0.30 | 0.21 | -4.50 | -12.24 | 29.52 | -4.60 | |
| Debt / EBITDA Ratio | - | - | - | - | - | 6.87 | |
| Asset Turnover | 0.09 | 0.04 | - | - | - | - | |
| Quick Ratio | 0.53 | 1.21 | 2.94 | 6.07 | 7.15 | 0.15 | |
| Current Ratio | 0.71 | 1.32 | 3.06 | 6.15 | 7.30 | 0.17 | |
| Return on Equity (ROE) | 1791.99% | 177.37% | - | - | - | - | |
| Return on Assets (ROA) | -39.55% | -34.92% | -27.24% | -23.39% | -26.97% | 5.31% | |
| Return on Capital (ROIC) | -44.45% | -38.49% | -33.91% | -27.79% | -28.97% | 7.72% | |
| Return on Capital Employed (ROCE) | -86.90% | -74.20% | -61.90% | -44.70% | -36.70% | -100.80% | |
| Earnings Yield | 9.07% | 168.09% | -250.86% | -56.18% | -18.90% | -4.28% | |
| FCF Yield | -149.14% | -222.45% | -386.66% | -78.52% | -17.42% | -75.55% | |
| Buyback Yield / Dilution | -157.30% | -106.41% | -107.22% | -33.56% | -27.37% | -35.70% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.